Netherlands Institute for Innovative Ocular Surgery, Rotterdam, The Netherlands; Melles Cornea Clinic, Rotterdam, The Netherlands; Amnitrans EyeBank, Rotterdam, The Netherlands.
Netherlands Institute for Innovative Ocular Surgery, Rotterdam, The Netherlands; Melles Cornea Clinic, Rotterdam, The Netherlands.
Ophthalmology. 2015 Jan;122(1):8-16. doi: 10.1016/j.ophtha.2014.07.024. Epub 2014 Sep 5.
To describe the clinical outcome and complications of repeat Descemet membrane endothelial keratoplasty (re-DMEK).
Retrospective case series study at a tertiary referral center.
From a series of 550 consecutive DMEK surgeries with ≥ 6 months follow-up, 17 eyes underwent re-DMEK for graft detachment after initial DMEK (n = 14) and/or endothelial graft failure (n = 3). The outcomes were compared with an age-matched control group of uncomplicated primary DMEK surgeries.
The re-DMEK eyes were evaluated for best-corrected visual acuity (BCVA), densitometry, endothelial cell density (ECD), pachymetry, and intraoperative and postoperative complications.
Feasibility and clinical outcome of re-DMEK.
In all eyes, re-DMEK was uneventful. At 12 months, 12 of 14 eyes (86%) achieved a BCVA of ≥ 20/40 (≥ 0.5); 8 of 14 eyes (57%) achieved ≥ 20/25 (≥ 0.8), 3 of 14 eyes (21%) achieved ≥ 20/20 (≥ 1.0), and 1 eye (7%) achieved 20/17 (1.2); 5 eyes were fitted with a contact lens. Average donor ECD decreased from 2580 ± 173 cells/mm(2) before to 1390 ± 466 cells/mm(2) at 6 months after surgery, and pachymetry from 703 ± 126 μm to 515 ± 39 μm, respectively. No difference in densitometry could be detected between re-DMEK and control eyes (P = 0.99). Complications after re-DMEK included primary graft failure (n = 1), secondary graft failure (n = 2), graft detachment requiring rebubbling (n = 1), secondary glaucoma (n = 2), cataract (n = 1), and corneal ulcer (n = 1). One eye received tertiary DMEK.
In the management of persistent graft detachment and graft failure after primary DMEK, re-DMEK proved a feasible procedure. Acceptable BCVA may be achieved, albeit lower than after DMEK in virgin eyes, and some cases may benefit from contact lens fitting. Complications after re-DMEK may be better anticipated than after primary DMEK because graft detachment and graft failure tended to recur, suggesting that intrinsic properties of the host eye play a role in graft adherence and graft failure.
描述重复 Descemet 膜内皮角膜移植术(re-DMEK)的临床结果和并发症。
在一家三级转诊中心进行的回顾性病例系列研究。
在一系列 550 例连续接受 DMEK 手术且随访时间≥6 个月的患者中,17 只眼因初次 DMEK 后(n=14)移植物脱离或(和)内皮移植物失败(n=3)而接受 re-DMEK。将这些结果与年龄匹配的无并发症初次 DMEK 手术的对照组进行比较。
评估 re-DMEK 眼的最佳矫正视力(BCVA)、密度测定、内皮细胞密度(ECD)、角膜厚度和术中及术后并发症。
re-DMEK 的可行性和临床结果。
所有 re-DMEK 手术均顺利完成。在 12 个月时,14 只眼中的 12 只(86%)获得了≥20/40(≥0.5)的 BCVA;14 只眼中的 8 只(57%)获得了≥20/25(≥0.8),3 只(21%)获得了≥20/20(≥1.0),1 只(7%)获得了 20/17(1.2);5 只眼需要配接触镜。供体 ECD 平均值从术前的 2580±173 个细胞/mm²降至术后 6 个月时的 1390±466 个细胞/mm²,角膜厚度从 703±126μm降至 515±39μm。re-DMEK 与对照组之间的密度测定无差异(P=0.99)。re-DMEK 术后的并发症包括初次移植物失败(n=1)、二次移植物失败(n=2)、需要重新注气的移植物脱离(n=1)、继发性青光眼(n=2)、白内障(n=1)和角膜溃疡(n=1)。1 只眼接受了三次性 DMEK。
在原发性 DMEK 后持续性移植物脱离和移植物失败的处理中,re-DMEK 是一种可行的方法。虽然术后 BCVA 低于初次性 DMEK,但可获得可接受的视力,且部分病例可能受益于接触镜配适。re-DMEK 后的并发症可能比初次性 DMEK 更可预测,因为移植物脱离和移植物失败往往会再次发生,这表明宿主眼的固有特性在移植物黏附和移植物失败中起作用。